Does Scripps Health Cover Dupixent?

What Scripps Health Actually Is and Why That Matters for Coverage

Scripps Health is a nonprofit integrated health system based in San Diego, California. It operates five hospitals, more than 30 outpatient facilities, and a large multispecialty medical group. What it is not is a health insurance company.

Your Dupixent coverage is determined by the insurance plan attached to your policy, whether that is a commercial carrier like Anthem, Aetna, Blue Shield of California, or Cigna, a Medicare Part D plan, Medi-Cal (California's Medicaid program), or an employer-sponsored self-funded plan. Scripps-affiliated physicians prescribe Dupixent and submit prior authorization paperwork on your behalf, but the approval or denial decision belongs entirely to your payer.

Why This Distinction Changes Your Strategy

Patients who call Scripps Health asking whether it "covers Dupixent" sometimes receive confusing answers because the question conflates provider and payer. Scripps providers can advocate for you, submit clinical documentation, and connect you with a specialty pharmacy. However, the actual benefit determination comes from the insurer listed on your insurance card.

Knowing this distinction lets you direct your questions to the right parties: your Scripps dermatologist or allergist for the clinical letter of medical necessity, and your insurance plan's pharmacy or medical benefits department for the actual coverage criteria.

Scripps-Affiliated Insurance Products

Scripps does participate in several plan networks through the Covered California exchange and through employer contracts in the San Diego region. If you enrolled in a plan specifically because it lists Scripps providers, the plan is still administered by a third-party insurer. Check the insurer name printed on your card, then call that insurer's specialty pharmacy line to ask for the Dupixent prior authorization criteria document, sometimes called a coverage policy bulletin.

What Is Dupixent and What Conditions Is It FDA-Approved to Treat?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. The FDA first approved it in March 2017 for moderate-to-severe atopic dermatitis in adults who are not adequately controlled with topical therapies or for whom those therapies are not advisable [1].

By 2024, the FDA label had expanded to six indications [2]:

1. Moderate-to-severe atopic dermatitis (adults and children as young as 6 months)
2. Moderate-to-severe asthma (ages 6 and older) as add-on maintenance therapy
3. Chronic rhinosinusitis with nasal polyps (adults)
4. Eosinophilic esophagitis (ages 12 and older, at least 40 kg)
5. Prurigo nodularis (adults)
6. Chronic obstructive pulmonary disease with type 2 inflammation (adults; approved June 2024)

Each indication carries its own prior authorization criteria, so the coverage pathway for a patient with asthma differs from that for a patient with atopic dermatitis, even if both see Scripps physicians.

Clinical Evidence Underpinning Coverage Decisions

Payers justify coverage criteria by referencing the key trial data. In the SOLO 1 and SOLO 2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an Investigator Global Assessment score of 0 or 1 in 37 to 38% of patients at 16 weeks versus 8 to 10% for placebo (P<0.0001) [3]. The LIBERTY AD CHRONOS trial (N=740) extended these findings to 52 weeks, showing that 39% of patients on dupilumab plus topical corticosteroids achieved clear or almost-clear skin versus 12% on placebo plus corticosteroids [4].

For asthma, the QUEST trial (N=1,902) demonstrated that dupilumab 200 mg every two weeks reduced severe exacerbation rates by 47.7% in patients with elevated eosinophils (eosinophils ≥300 cells/µL) compared with placebo [5]. These numbers are what clinical reviewers at insurers look at when they evaluate your prior authorization.

Dosing Schedules That Affect Pharmacy Benefits vs. Medical Benefits

Dupixent is administered by subcutaneous injection. For atopic dermatitis in adults, the approved loading dose is 600 mg (two 300 mg injections), followed by 300 mg every other week. Some pediatric dosing schedules call for monthly injections. The route and frequency matter because some plans cover biologics under the pharmacy benefit (patient picks up prefilled syringes at a specialty pharmacy), while others cover them under the medical benefit (administered in a Scripps clinic and billed as a physician-administered drug). Medical-benefit coverage often carries different cost-sharing than pharmacy-benefit coverage [6].

How Prior Authorization Works for Dupixent

Prior authorization (PA) is the single biggest variable in whether you get Dupixent covered promptly or face delays. Almost every payer that covers dupilumab requires PA, and criteria vary by insurer and indication [7].

Typical Step-Therapy Requirements

Most commercial plans require documentation that you have tried and had an inadequate response to at least one or two conventional treatments before approving Dupixent. For atopic dermatitis, that usually means topical corticosteroids (such as triamcinolone or clobetasol) and often a topical calcineurin inhibitor like tacrolimus or pimecrolimus. Some plans also require a trial of systemic agents such as methotrexate or cyclosporine.

The American Academy of Dermatology's 2023 guidelines state that dupilumab is recommended for patients with moderate-to-severe atopic dermatitis when topical therapies do not provide adequate control or are not appropriate [8]. Your Scripps dermatologist should reference this guideline directly in the PA letter.

What the Letter of Medical Necessity Must Include

A well-constructed letter of medical necessity from a Scripps physician typically documents:

• Confirmed diagnosis with ICD-10 code (for atopic dermatitis, L20.9)
• Disease severity score such as an IGA score of 3 or 4, or an EASI score above 16
• Names, doses, and durations of prior therapies tried
• Documented treatment failure, intolerance, or contraindication
• Why dupilumab specifically is appropriate for this patient

Missing even one element can trigger an automatic denial, so ask your Scripps provider to use a PA template specific to your insurer.

Timelines to Expect

Standard PA decisions are required within 3 business days for non-urgent requests and 24 hours for urgent requests under California law (Knox-Keene Act). Specialty drug PAs sometimes stretch to 14 days if the insurer requests additional clinical records. If you have not received a decision within 5 business days of submission, call your insurer and ask for the status; California Insurance Code Section 10123.135 requires timely processing.

What Happens When Dupixent Is Denied

Denial is not the end. Data from a 2022 analysis published in JAMA Internal Medicine found that patients who appealed specialty drug denials succeeded in reversing the decision in approximately 45% of cases at the first internal appeal level [9]. A formal appeal supported by clinical literature is meaningfully more likely to succeed than one submitted without additional documentation.

Internal Appeal

File the internal appeal within the timeframe printed on your denial letter, typically 30 to 180 days. Attach the key trial publications (SOLO 1/2, CHRONOS, or QUEST depending on your indication), the AAD or GINA guideline recommendation, and a signed letter from your Scripps physician explaining why alternative therapies failed or are contraindicated.

External Independent Medical Review

California law (Health and Safety Code Section 1374.30) gives you the right to an Independent Medical Review (IMR) by a state-contracted reviewer when the insurer upholds its denial internally. The California Department of Managed Health Care reported that biologics for dermatologic conditions were overturned in the patient's favor in roughly 63% of IMR cases reviewed in 2022 [10]. Submit the IMR application to the DMHC at the same time you file your internal appeal to save weeks.

Expedited Reviews

If your condition is severe enough that a standard timeline would seriously jeopardize your health, request an expedited review. Physicians can certify medical urgency, which compresses the insurer's review window to 72 hours under California law.

Dupixent Cost and Patient Assistance Programs

Even with insurance approval, cost-sharing can be substantial. The wholesale acquisition cost of Dupixent is approximately $3,200 per prefilled syringe (300 mg), placing the annual list price near $37,500, $40,000 for the standard every-other-week adult atopic dermatitis regimen. Real-world negotiated prices paid by insurers are lower, but patient cost-sharing under high-deductible plans can still reach thousands of dollars per year.

Dupixent MyWay Copay Card (Commercially Insured Patients)

Sanofi and Regeneron jointly operate the Dupixent MyWay program. Commercially insured patients who meet income and eligibility criteria may pay as little as $0 per month, with the program covering up to $13,000 per year in copay costs. Eligibility is confirmed online or by calling 1-844-DUPIXENT. Patients on Medicare, Medicaid, or other government programs are not eligible for the copay card due to federal anti-kickback statutes [11].

Patient Assistance Program for Uninsured or Underinsured Patients

For patients without commercial insurance or who cannot afford their share of costs even with a copay card, Sanofi's patient assistance program (PAP) may provide Dupixent at no charge. Income thresholds and enrollment documentation requirements apply. A Scripps social worker or financial counselor can help complete the paperwork.

Medi-Cal Coverage in California

California's Medi-Cal program covers dupilumab for atopic dermatitis under the Medi-Cal Rx formulary, subject to prior authorization. As of the 2024 Medi-Cal Rx preferred drug list update, dupilumab requires PA with documentation of inadequate response to at least one topical corticosteroid. Patients enrolled in Medi-Cal Managed Care plans may face slightly different criteria depending on their managed care organization.

Medicare Part D Coverage

Most Medicare Part D stand-alone drug plans and Medicare Advantage prescription drug plans place dupilumab on Tier 4 or Tier 5 (specialty tier). Standard Part D cost-sharing for specialty drugs in 2024 was capped at 25% coinsurance until the catastrophic threshold. Beginning in 2025, the Inflation Reduction Act caps Medicare out-of-pocket drug costs at $2,000 per year, which meaningfully lowers the annual burden for dupilumab users on Medicare [12].

Working With Your Scripps Physician to Maximize Approval Odds

The framework below reflects the workflow our clinical team recommends when a Scripps-affiliated patient needs dupilumab approved as efficiently as possible.

Step 1: Get the Right Diagnosis Documentation at Your First Visit

Ask your Scripps dermatologist to document your IGA score, body surface area involvement, EASI score, and prior treatment history in the visit note. This single step prevents the most common PA delay: an insurer returning the request for "insufficient clinical information."

Step 2: Request the Insurer's Specific PA Criteria Document Before Submission

Call your insurer's specialty pharmacy line and ask for the dupilumab clinical coverage policy bulletin. Read it before your Scripps provider submits the PA. If the policy requires a 6-week trial of triamcinolone 0.1% and your records only document 4 weeks, schedule a brief visit with your provider to extend the trial and re-document before submitting.

Step 3: Use a Specialty Pharmacy Preferred by Your Plan

Scripps works with multiple specialty pharmacies. Ask your insurer which specialty pharmacy is preferred for your plan; using a non-preferred specialty pharmacy can trigger automatic denial or higher cost-sharing even after PA approval. CVS Specialty, Walgreens Specialty, and Accredo are commonly preferred for California commercial plans.

Step 4: Confirm Benefit Channel (Pharmacy vs. Medical Benefit)

Ask your Scripps provider's office whether Dupixent will be billed through pharmacy benefit (patient self-injects at home) or medical benefit (administered at a Scripps infusion center or office). Your out-of-pocket costs can differ substantially. In 2023, a Health Affairs analysis found that biologic drugs covered under the medical benefit carried average patient cost-sharing 31% higher than the same drugs covered under pharmacy benefit for patients in high-deductible plans [13].

Step 5: Set a Follow-Up PA Renewal Calendar Alert

Most insurers require PA renewal every 12 months. Set a reminder 60 days before your PA expires. Gaps in coverage can interrupt therapy, and trial data from CHRONOS showed that patients who discontinued dupilumab and then restarted had statistically lower response rates at week 52 compared with continuous-therapy patients [4].

Conditions Covered by Dupixent: Indication-Specific Coverage Notes

Atopic Dermatitis

This is the most commonly approved indication and the one with the most strong payer coverage policy infrastructure. All major California commercial carriers, Medi-Cal, and Medicare Part D plans cover dupilumab for moderate-to-severe atopic dermatitis with PA. Pediatric coverage (ages 6 months to 17 years) follows the same step-therapy logic but may require pediatric-specific IGA documentation [14].

Asthma

Dupixent for asthma is typically covered under the pharmacy benefit but may require documentation of blood eosinophil count ≥150 cells/µL or fractional exhaled nitric oxide (FeNO) ≥25 ppb. The Global Initiative for Asthma (GINA) 2023 report recommends add-on biologic therapy for step 5 uncontrolled asthma and lists dupilumab as an option for patients with type 2 inflammation [15]. Your Scripps pulmonologist or allergist should include the eosinophil count from recent labs in the PA letter.

Chronic Rhinosinusitis With Nasal Polyps

Coverage for this indication often sits under the medical benefit, billed through ear-nose-throat or allergy offices. PA criteria typically require prior sinus surgery or documented polyp burden on CT imaging. A 2019 New England Journal of Medicine publication of the SINUS-52 trial (N=297) showed that dupilumab reduced nasal polyp score by 2.06 points versus 0.09 for placebo over 52 weeks (P<0.001) [16], and this trial is the anchor citation most insurers accept.

Eosinophilic Esophagitis

This is one of the newer indications and coverage policies are still maturing. Several California commercial plans have issued positive coverage bulletins as of late 2024, but some still classify dupilumab for EoE as investigational. Your Scripps gastroenterologist should reference the key BOREAS trial data and the FDA label approval date (May 2022) in any PA submission [17].

Prurigo Nodularis

Coverage for prurigo nodularis is available on most commercial formularies as of 2024, following FDA approval in September 2022. Payer criteria typically require documentation of at least 20 nodules and inadequate response to high-potency topical corticosteroids.

Special Situations: Medicare, Medicaid, and Self-Pay at Scripps

Medicare Patients at Scripps

Scripps Health treats a large Medicare population. If you are on Medicare, dupilumab falls under Part D (pharmacy benefit) or Part B (medical benefit if provider-administered). Part B coverage requires a J-code billing submission (J0173 for dupilumab as of the 2024 HCPCS update) from your Scripps physician's office. Part B does not have a formulary per se, but coverage is contingent on medical necessity documentation [6].

Medi-Cal Managed Care Patients

Patients enrolled in a Medi-Cal managed care plan through a plan such as Molina, Health Net, or Blue Shield Promise at Scripps should direct PA questions to the managed care plan, not Medi-Cal Rx directly. Managed care plans have their own formulary committees and may add criteria beyond the Medi-Cal Rx baseline.

Self-Pay Patients

Without insurance, the list price of dupilumab at a Scripps-affiliated specialty pharmacy would be approximately $3,200 per syringe. The Sanofi PAP is the most practical option. A Scripps financial counselor can initiate enrollment; the program processes applications in approximately 3 to 5 business days.

Monitoring and Safety Considerations While on Dupixent at Scripps

Dupixent does not require the routine laboratory monitoring that older immunosuppressants like methotrexate or cyclosporine require. The prescribing label notes no requirement for routine CBC, hepatic function, or creatinine monitoring [2]. Your Scripps provider will typically schedule clinical assessments at 16 weeks to evaluate treatment response before submitting the first PA renewal.

Conjunctivitis is the most common adverse event reported with dupilumab, occurring in approximately 10% of atopic dermatitis patients in clinical trials [3]. Scripps dermatologists typically refer affected patients to an affiliated ophthalmologist for evaluation. Rare reports of eosinophilia have been documented, and the FDA label advises monitoring if eosinophilic conditions develop during treatment [2].